Story
Genhouse Bio Refiles for Hong Kong IPO Following $80M Upfront Payment from Gilead

Chinese oncology drug developer Genhouse Bio (Suzhou) Co., Ltd. has refiled for an initial public offering on the Hong Kong Stock Exchange, according to a prospectus submitted on August 7. The move is supported by a significant financial turnaround, driven by a lucrative licensing deal with U.S. pharmaceutical giant Gilead Sciences.
Gilead Deal Transforms Financials
Genhouse Bio reported a dramatic surge in revenue to CNY 558 million (approx. $77 million) for the first five months of the year, a stark contrast to the full-year revenues of CNY 4.69 million and CNY 1.27 million in the two preceding years. The company's prospectus attributes this growth primarily to a global licensing agreement for its synthetic lethality drug candidate, GH31.
The deal with Gilead, finalized in February, included a non-refundable upfront payment of $80 million. This influx of capital enabled the company to swing from significant annual losses to profitability. For the five-month period, Genhouse Bio posted a net profit of CNY 355 million, reversing net losses of CNY 152 million and CNY 144 million recorded in the previous two fiscal years.
Strategic Focus on Oncology Pipeline
Founded in 2014, Genhouse Bio focuses on developing targeted cancer therapies centered on the RAS signaling pathway and synthetic lethality mechanisms. According to the filing, its pipeline consists of eight drug candidates, including four in clinical stages and one that has received Investigational New Drug (IND) approval from both U.S. and Chinese regulators.
AdBeyond the Gilead partnership, the company has other key collaborations:
- A 2020 agreement granted HUYABIO International exclusive rights to develop and commercialize its SHP2 inhibitor, GH21, outside of Greater China in a deal potentially worth up to $282 million.
- The company is also engaged in clinical supply and joint therapy development agreements with AstraZeneca and Shanghai Zhengda Tianqing Pharmaceutical.
Market Outlook and IPO Details
Genhouse Bio's strategic focus is on a rapidly growing segment of the pharmaceutical market. Citing data from China Insights Consultancy, the prospectus notes that the global market for synthetic lethality drugs is projected to expand from $4.8 billion in 2025 to $17.4 billion by 2033.
This is the company's second attempt to list on the HKEX main board, following an initial application in January. Huatai International is acting as the sole sponsor for the proposed listing.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.